Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1608P - The impact of COVID-19 on the delivery of systemic anti-cancer treatment at Guy’s Cancer Centre


16 Sep 2021


ePoster Display


Saoirse Dolly


Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713


S. Dolly1, B. Russell2, C.L. Moss2, E. Tsotra1, C. Gousis1, J. Roca1, A. Sita-Lumsden1, M. Khan3, D. Josephs4, K. Zaki1, D. Smith1, V. Michalarea1, R. Kristeleit5, D. Enting6, L. Flanders1, M. Lei1, E. sawyer2, J. Spicer2, P. Ross7, A. Montes3, M. Van Hemelrijick8

Author affiliations

  • 1 Guy's Cancer, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 2 Comprehensive Cancer Centre, KCL - King's College London, WC2R 2LS - London/GB
  • 3 Medical Oncology, Guy's & St. Thomas' NHS Foundation Trust, SE19RT - London/GB
  • 4 Medical Oncology Department, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 5 Department Of Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London/GB
  • 6 Department Of Oncology, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 7 Medical Oncology, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 8 Translational Oncology And Urology Research, King's College London, London/GB


Abstract 1608P


Early reports in the COVID-19 pandemic suggested higher mortality for cancer patients. The impact of potentially immunosuppressive systemic anti-cancer treatments (SACT) was unknown. This study analysed the delivery of SACT for patients with solid malignancies during the COVID-19 outbreak in 2020 compared to the same period in 2019 to inform future clinical decision-making.


All patients receiving at least one SACT at Guy's comprehensive Cancer Centre during the COVID-19 outbreak for solid tumours (1st March- 31st May 2020) were compared to the same period in 2019. SARS-CoV2 infection was by positive RT-PCR test. Data collected: demographics, tumour type/stage and treatment (chemotherapy, immunotherapy (IO), biological-targeted (BT)).


2125 patients received SACT in 2020, compared to 2450 in 2019 (13% decrease). Demographics were comparable with mean age of 62. 56% females in 2020 vs 54% in 2019, 85% vs 83% in the low socio-economic category, 63% vs 73% PS 0-1; 30% vs 29% uro-gynaecological, 27% vs 24% breast and 20% vs 23% GI tumours. In 2020 compared to 2019, there was an increase in metastatic disease (71% vs 62%), decrease in CT (34% vs 42%), increase in IO (10% vs 6%), but similar rates of BT treatments (38% vs 37%). Treatment paradigms were similar in 2020 and 2019: neo/adjuvant (28% vs 29%), radical (4% vs 5%) and palliative (69% vs 67%). Earlier palliative treatments were prioritised in 2020 with significant increase in treatments in 1st-2nd line (72% vs 67%; p=0.02) and reduction in > 3rd line (12% vs 27%; p<0.05). 42 of 2125 patients (2%) developed SARS-CoV2 infections; 38% GI, 26% breast with 69% on CT. Of 42 patients with COVID-19, 24 (57%) had severe infections and 6 (14%) resulted in COVID-related death.


These data suggest that SACT does not put solid tumour patients at much a higher additional risk from COVID-19. Despite a 13% decline in treatment rates, radical and early palliative treatment were prioritised. There was a low frequency (2%) of SARS-CoV-2 infection; comparable to the 1.4% point prevalence rate in our cancer population. However, this was during national lockdown with limited COVID-19 testing. The next steps are to evaluate the impact of new variant strains and COVID vaccination programme.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Guy's Real-World Evidence.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings